Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13Sarcoma, Myeloid 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Promyelocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 26fludarabine 18Dexamethasone 17pembrolizumab 12Rituximab 11Etoposide 10venetoclax 9pomalidomide 9Gemcitabine 9fludarabine phosphate 7daratumumab 7Lenalidomide 7Bortezomib 7carfilzomib 6obinutuzumab 5glofitamab 5Vincristine 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Doxorubicin 4Cytarabine 4Carboplatin 4zanubrutinib 3ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Mitoxantrone × 90 days × Clear all
NCT01279096 2026-04-22

Vandevol

University Hospital, Lille

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06660368 2026-04-01

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
52 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡